4.6 Review

Which hidradenitis suppurativa comorbidities should I take into account?

Journal

EXPERIMENTAL DERMATOLOGY
Volume 31, Issue -, Pages 29-32

Publisher

WILEY
DOI: 10.1111/exd.14633

Keywords

clinical significance; comorbidities; depression; hidradenitis suppurativa; inflammatory bowel disease; metabolic syndrome; quality of life; working disability

Categories

Ask authors/readers for more resources

Hidradenitis suppurativa is a chronic skin inflammatory disease associated with various comorbidities, including cardiovascular diseases and increased suicide risk. It is important for clinicians to be aware of these comorbidities and design appropriate treatment strategies.
Hidradenitis suppurativa (HS) is a chronic, recurrent skin inflammatory disease associated with a variety of comorbidities, like metabolic syndrome, reduced quality of life, sexual dysfunction, working disability, inflammatory bowel disease, axial spondyloarthritis, depression and anxiety. Like psoriasis, HS patients have been found to have higher risk of cardiovascular death and suicide risk. Evidence suggests that for such a chronic, multi-comorbid disease, the use of validated outcomes to assess severity and effect of treatment, along with the use of clinically important patient reported outcomes, is essential. Clinicians should be informed about these comorbidities so that appropriate screening is implemented. The potential of available treatments to negatively and positively affect these comorbidities should also be taken into account when designing treatment strategies. This article aims to provide an outline of important HS comorbidities with emphasis on possible implications for daily clinical practice.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available